genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Cancer
Changing Carcinogenic Cells in the Lungs with Novel Technology
Gastrointestinal Disorders
GI GVHD Link to Microbiome Dysbiosis Addressed by Reducing Intestinal Oxygen
Cancer
Molecular Anchor Creates More Effective CAR T Immunotherapies
Cancer
White House Continues Dedication to “End Cancer as We Know It”
Cancer
Molecular Pathways Used by Metastatic Cancer Cells Uncovered
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
OMICs
Reflections on the Double Helix’s Platinum Anniversary
Artificial Intelligence
AI and Computational Design Advance Protein Engineering
Bioprocessing
In Pursuit of Rare, Subtle, and Fleeting Post-Translational Modifications
Infectious Diseases
Tripledemic Rouses Vaccine Developers and Variant Trackers
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Companies
shire
shire
23andMe
Abbvie
AdnaGen
Agilent Technologies
Alexion Pharmaceuticals
Amgen
Astellas
AstraZeneca
Audentes Therapeutics
Berkeley Lights
Bio-Rad Laboratories
Biogen
Cancer Genetics
Catalent
Charles RIver Laboratories
Dana-Farber Cancer Institute
deCODE genetics
Dicerna
Dimension Therapeutics
Exact Sciences
Foundation Medicine
GE Healthcare
GeneInsight
Gilead Sciences
GlaxoSmithKline
Halozyme Therapeutics
Hitachi High-Technologies
Horizon Discovery Group
Human Longevity
Illumina
Jackson Laboratory
Janssen Biotech
LabCorp
Maravai LifeSciences
MD Anderson
MDxHealth
MedImmune
Memorial Sloan Kettering Cancer Center
Merck & Co
Merck KGaA
NanoString Technologies
Novartis
Pathology
PerkinElmer
PersonalizeDx
Qiagen
RayBiotech
Roche
Sanofi
shire
Sigma-Aldrich
Synthego
Takeda
Thermo Fisher Scientific
UCB Biosciences
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
shire
Shire, Takeda Shareholders Approve $58.5B Acquisition Deal
shire
Shire Licenses Rare Liver Disease Candidates to $120M Startup Mirum
shire
Sanofi Pasteur, Translate Bio Launch mRNA Vaccine Partnership
shire
Shire, Takeda Come to Terms on $62B Acquisition Deal
shire
Shire Board Sets Stage for $64B Takeda Acquisition, If Companies Resolve Details
shire
Shire Rejects Takeda Takeover Bids
shire
Servier to Acquire Shire’s Oncology Business for $2.4B
shire
Shire Pursues FDA Approval for Plasma Manufacturing Facility
shire
Lonza Expands in Mammalian Manufacturing with Purchase of California Site
shire
Shire Transfers IND for GvHD Candidate to Kamada
shire
Shire Hemophilia Candidate Using Xenetic Platform Falls Short in Trial
shire
Shire Plans Lanadelumab BLA Submission Following Positive Phase III HAE Results
shire
Shire, Parion Ink Deal for Up to $535M to Develop Phase...
shire
EC Approves Shire’s Recombinant Parathyroid Hormone for Hypoparathyroidism
shire
RaNA Therapeutics Acquires Shire’s mRNA Platform
Scroll Up
Login
Subscribe